Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822740 | 0.78 | GAA (0.48) | GAAABL1KMT2AKDM4E | |
| SCHEMBL12458294 | 0.78 | GAA (0.39) | GAAABL1KMT2AKDM4E | |
| SCHEMBL25353502 | 0.76 | GAA (0.42) | GAA | |
| SCHEMBL20886078 | 0.76 | ABL1 (0.40) | GAAKCNH2ABL1ALOX5APFEN1 | |
| SCHEMBL14805637 | 0.76 | GAA (0.34) | GAAABL1 | |
| SCHEMBL17471316 | 0.76 | NOS3 (0.45) | ALOX5APFEN1KDM4EPOLBRAB9A | |
| SCHEMBL19251577 | 0.73 | PKM (0.36) | NUDT1KDM4ERAB9ALMNAMAPT | |
| SCHEMBL14805786 | 0.73 | GAA (0.30) | GAA | |
| SCHEMBL18484544 | 0.73 | MAPK8 (0.35) | GAAABL1ALOX5APFEN1KMT2A | |
| SCHEMBL504264 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | NUDT1 463/4885GAA 85/4885KCNH2 4033/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NUDT1 537/4885GAA 1078/4885KCNH2 2571/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | NUDT1 379/4885GAA 82/4885KCNH2 3983/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | NUDT1 463/4885GAA 85/4885KCNH2 4033/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NUDT1 537/4885GAA 1078/4885KCNH2 2571/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | NUDT1 463/4885GAA 85/4885KCNH2 4033/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | NUDT1 379/4885GAA 82/4885KCNH2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.